[go: up one dir, main page]

PE20010649A1 - Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos - Google Patents

Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos

Info

Publication number
PE20010649A1
PE20010649A1 PE2000000890A PE0008902000A PE20010649A1 PE 20010649 A1 PE20010649 A1 PE 20010649A1 PE 2000000890 A PE2000000890 A PE 2000000890A PE 0008902000 A PE0008902000 A PE 0008902000A PE 20010649 A1 PE20010649 A1 PE 20010649A1
Authority
PE
Peru
Prior art keywords
muscarinal
antranylamide
antagonists
derivatives
substituted piperidines
Prior art date
Application number
PE2000000890A
Other languages
English (en)
Inventor
Joseph A Kozlowski
John W Clader
Susan F Vice
Stuart W Mccombie
Michael W Miller
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010649A1 publication Critical patent/PE20010649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A 2-AMINOBENZAMIDA O 2-AMINOPIRIDINCARBOXAMIDA DE FORMULA I, DONDE Q Y Q` SON -CH=, UNO ES -CH= Y EL OTRO ES -N=; X ES CH2, GRUPO a, Z E Y SON C(R5)=, UNO ES C(R5)= Y EL OTRO ES -N=; R1 ES H, HALOGENO, ALCOXI C1-C6, R2 Y R5 SON H, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6; R3 Y R4 SON H, ALQUILO C1-C6. TAMBIEN SE REFIERE AL USO COMBINADO CON UN INHIBIDOR DE ACETILCOLINESTERASA. LOS COMPUESTOS PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES COGNITIVAS O NEURODEGENERATIVAS
PE2000000890A 1999-09-22 2000-08-31 Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos PE20010649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22

Publications (1)

Publication Number Publication Date
PE20010649A1 true PE20010649A1 (es) 2001-06-19

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000890A PE20010649A1 (es) 1999-09-22 2000-08-31 Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos

Country Status (14)

Country Link
EP (1) EP1214299B1 (es)
JP (1) JP2003509494A (es)
CN (1) CN1167682C (es)
AR (1) AR025459A1 (es)
AT (1) ATE264301T1 (es)
AU (1) AU5786300A (es)
CA (1) CA2384018C (es)
CO (1) CO5180624A1 (es)
DE (1) DE60009931T2 (es)
ES (1) ES2215055T3 (es)
HK (1) HK1043590A1 (es)
MX (1) MXPA02003136A (es)
PE (1) PE20010649A1 (es)
WO (1) WO2001021590A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
EP1434766B1 (en) * 2001-10-10 2006-08-02 Schering Corporation Piperidine compounds as muscarinic antagonists
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
PE20181010A1 (es) * 2015-11-06 2018-06-26 Neurocrine Biosciences Inc Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
AR019167A1 (es) * 1998-06-30 2001-12-26 Schering Corp Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos

Also Published As

Publication number Publication date
CO5180624A1 (es) 2002-07-30
CN1374949A (zh) 2002-10-16
WO2001021590A1 (en) 2001-03-29
CN1167682C (zh) 2004-09-22
DE60009931D1 (de) 2004-05-19
EP1214299A1 (en) 2002-06-19
ATE264301T1 (de) 2004-04-15
JP2003509494A (ja) 2003-03-11
ES2215055T3 (es) 2004-10-01
AU5786300A (en) 2001-04-24
HK1043590A1 (zh) 2002-09-20
AR025459A1 (es) 2002-11-27
CA2384018A1 (en) 2001-03-29
DE60009931T2 (de) 2005-04-07
MXPA02003136A (es) 2002-09-30
CA2384018C (en) 2010-01-12
EP1214299B1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
AR029614A1 (es) Derivados de 4-fenil-piridina, su uso, un proceso para prepararlos, y medicamentos que los contienen
ECSP034431A (es) N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
ES2135543T3 (es) Piperidinas (4-aril-sustituidas) como antagonistas de los receptores de neuroquininas.
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
DK0979821T3 (da) Tricykliske forbindelser
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
PE20040645A1 (es) Derivados de indolinfenilsulfonamida
DE69820159D1 (de) Therapeutisch nützliche Chinoline und Quinazoline
YU68896A (sh) Jedinjenja hinolina i nihazolina od koristi u terapiji
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR029400A1 (es) Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende
ATE144511T1 (de) Tetrahydrobenzimidazol-derivate
PE75199A1 (es) Derivado de quinolina util como antagonista de neuroquinina
AR018370A1 (es) Inhibidores de proteasas, composiciones farmaceuticas que lo comprenden, uso de los mismos para la manufactura de un medicamento
DK0875506T3 (da) Quinolin- og quinazolin-forbindelser, som er anvendelige til behandling
AR015514A1 (es) Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
AR006189A1 (es) Aminoalquil-eteres y acilaminoalquil-eteres, procedimiento para su preparacion y su utilizacion como antagonistas de receptores de bradiquinina
AR041481A1 (es) Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
ES2058247T3 (es) 4-hidroxicinnolin-carboxamidas, su utilizacion y metodo de preparacion.

Legal Events

Date Code Title Description
FD Application declared void or lapsed